Long-acting insulin is a synthetic form of insulin designed to provide a steady, basal level of insulin throughout the day or night. It is a hormone, naturally produced by the pancreas, essential for regulating glucose (sugar) in the bloodstream. In individuals with diabetes, either the body does not produce enough insulin (Type 1 diabetes) or does not use insulin effectively (Type 2 diabetes). Long-acting insulin helps to maintain blood sugar levels between meals and overnight, preventing hyperglycemia (high blood sugar). Common brand names include Lantus (insulin glargine) and Basaglar (insulin glargine). It is administered via subcutaneous injection, usually once or twice daily, depending on the specific product and individual needs. Long-acting insulin is a prescription medication and its use requires careful monitoring by a licensed healthcare professional.
Since this compound is injectable, proper administration techniques, including sterile preparation and rotation of injection sites, are crucial to minimize risks and ensure effectiveness. As a controlled medication, its use is strictly regulated and requires ongoing medical supervision.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Compound-pair rule
Caution
GLP-1 plus basal insulin increases hypoglycemia risk.
Reduce basal insulin dose 10–20% at GLP-1 initiation and titrate.
Frequently asked
Sources referenced
["PubChem (National Library of Medicine)", "DrugBank (University of Alberta)", "EMA SmPC (European Medicines Agency Summary of Product Characteristics)", "FDA label (U.S. Food and Drug Administration)", "NIH ODS (National Institutes of Health Office of Dietary Supplements - general information on hormones, not specific to this compound)", "MedlinePlus (National Library of Medicine)", "Cochrane Library (Cochrane Collaboration)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.